Scarica l'app Stockscreener
2.24
18.52%
0.35
Dopo l'orario di chiusura:
2.18
-0.06
-2.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Humacyte Inc Borsa (HUMA) Ultime notizie
Humacyte’s Earnings Call Highlights Success and Challenges - TipRanks
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates - MSN
Humacyte (HUMA) Receives Buy Rating and $4.00 Price Target from HC Wainwright & Co. | HUMA Stock News - GuruFocus
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock New - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating By Investing.com - Investing.com South Africa
Humacyte (HUMA) Reports Lower-Than-Expected Q1 Revenue Amid Symv - GuruFocus
Humacyte, Inc.: Spare Parts for People - Outsider Club
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Benchmark cuts Humacyte stock target to $14, maintains Buy rating - Investing.com
Humacyte (HUMA) Price Target Reduced by Benchmark Amid Positive Outlook | HUMA Stock News - GuruFocus
Humacyte (HUMA) Focuses on Symvess Launch and Expansion Plans - GuruFocus
Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call Transcript - Insider Monkey
Humacyte price target lowered to $14 from $17 at Benchmark - TipRanks
Durham firm with battered stock cuts jobs to save cash - The Business Journals
Humacyte Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surges - Investing.com Nigeria
Humacyte, Inc. SEC 10-Q Report - TradingView
Positive Momentum and Financial Stability Drive Buy Recommendation for Humacyte - TipRanks
Humacyte (HUMA) Receives Continued 'Buy' Rating from Analyst | - GuruFocus
Transcript : Humacyte, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Humacyte (HUMA) Anticipates Q1 Earnings Announcement - GuruFocus
Humacyte, Inc. Reports First Quarter 2025 Financial Results and Market Launch of Symvess™ for Vascular Trauma Treatment - Nasdaq
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update - TradingView
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Humacyte Q1 2025 Earnings Call Transcript - MarketBeat
Levi & Korsinsky Notifies Shareholders of Humacyte, Inc. (HUMA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
HUMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
HUMA Shareholders Have Opportunity to Lead Humacyte, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - ACCESS Newswire
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 - The Manila Times
Humacyte, Inc. to Release First Quarter 2025 Financial Results on May 13, 2025 - Nasdaq
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA ViolationsHagens Berman - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - MSN
Humacyte Insiders Placed Bullish Bets Worth US$949.4k - Yahoo Finance
All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy - Yahoo Finance
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):